LUMOS DIAGNOSTICS HOLDINGS LIMITED Lumos Diagnostics Holdings Limited Share Price
Equities
LDX
AU0000157091
Medical Equipment, Supplies & Distribution
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.052 AUD | -5.45% |
|
-7.14% | -28.77% |
| Sales 2022 | 11.63M 7.63M 610M | Sales 2023 | 10.54M 6.91M 552M | Capitalization | 2.27M 1.49M 119M |
|---|---|---|---|---|---|
| Net income 2022 | -45M -29.53M -2.36B | Net income 2023 | -8M -5.25M -419M | EV / Sales 2022 | 1.68 x |
| Net cash position 2022 | 784K 515K 41.09M | Net Debt 2023 | 6.77M 4.44M 355M | EV / Sales 2023 | 0.86 x |
| P/E ratio 2022 |
-0.32
x | P/E ratio 2023 |
-0.19
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 69.71% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -5.45% | ||
| 1 week | -7.14% | ||
| Current month | -14.75% | ||
| 1 month | -16.13% | ||
| 3 months | -28.77% | ||
| 6 months | -29.73% | ||
| Current year | -28.77% |
1 week
0.05
0.06
1 month
0.050.07
Current year
0.050.11
1 year
0.010.18
3 years
0.011.50
5 years
0.011.50
10 years
0.011.50
| Managers | Title | Age | Since |
|---|---|---|---|
Douglas Ward
CEO | Chief Executive Officer | - | 20/06/22 |
Barrie Lambert
DFI | Director of Finance/CFO | - | 15/02/22 |
Sam Lanyon
CHM | Chairman | - | 31/12/18 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Lawrence Mehren
BRD | Director/Board Member | 57 | 31/10/20 |
Bronwyn Le Grice
BRD | Director/Board Member | - | 31/10/20 |
Douglas Ward
CEO | Chief Executive Officer | - | 20/06/22 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 29/04/24 | 0.052 | -5.45% | 1 477 633 |
| 26/04/24 | 0.055 | -3.51% | 1,227,629 |
| 24/04/24 | 0.057 | -1.72% | 2,481,838 |
| 23/04/24 | 0.058 | +3.57% | 12,200,090 |
| 22/04/24 | 0.056 | 0.00% | 2,066,138 |
Delayed Quote Australian S.E., April 29, 2024 at 03:21 am
More quotes
Lumos Diagnostics Holdings Ltd is an Australia-based company, which specializes in point-of-care (POC) diagnostic test technology to help healthcare professionals diagnose and manage medical conditions. The Company offers customized assay development and manufacturing services for POC tests and digital reader platforms. It also directly develops, manufactures, and commercializes, Lumos-branded POC tests that target infectious and inflammatory diseases. The Companyâs products include FEBRIDX, COVIDX, and ViraDx. FebriDx is a point-of-care test which can be used to detect and aid in differentiating bacterial from viral acute respiratory infections. ViraDx is a point-of-care, three-in-one COVID-19/Flu A/Flu B rapid antigen test. Its services include assay development, reader development, cloud and data, and manufacturing. It manages the full development program for point-of-care (POC) assays, from sourcing and/or generation of reagents, right through to verification and validation.
Calendar
19/08/2024
- Q4 2024 Earnings Release (Projected)
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -28.77% | 17.26M | |
| +0.89% | 12.8B | |
| -10.29% | 7.61B | |
| -1.16% | 4.51B | |
| +5.74% | 4.49B | |
| -50.70% | 3.3B | |
| +12.21% | 2.73B | |
| -16.13% | 2.02B | |
| -11.50% | 1.73B | |
| -5.02% | 1.64B |
- Stock Market
- Equities
- LDX Stock
